BioTime has formed a new science and technology committee to oversee the development and commercialization of its regenerative medicine and oncology tech.
Newly appointed director and former US FDA commissioner Andrew von Eschenbach joins the three-member committee alongside Optimer Pharmaceuticals CEO Pedro Lichtinger, and Neal Bradsher who is president of Broadwood Capital.
“The committee looks forward to working with the management of BioTime and its subsidiaries in advancing breakthrough products into clinical trials, including those anticipated to begin this year for the use of HyStem-Rx as an implantable matrix for cell delivery in cosmetic and reconstructive surgeries,” said von Eschenbach.
Alfred Kingsley, BioTime chairman, added: “This is an exciting time for the emerging field of regenerative medicine.”
This week's pharmaceutical changes begin with the election of Reuters' head to the Board of Pfizer.
Big changes in biologics in this week's column, as we round up the pharma industry's new scientific...
Plus the small companies which have hired senior scientists from Bristol-Myers Squibb and Merck Serono.
Plus senior pharma hires in the US and Asia in this week's column.
Pharma's latest movers include former senior employees of AstraZeneca, Roche and Novartis.